COMPANY PROFILE

Navitor

Explore full profile

A biopharmaceutical company that develops novel medicines.

Cambridge, United StatesFounded 2010Biotech & Life Sciences

Valuation $100–250M Last recorded · 2020

Headcount <100 Current team size

Total funding $50–100M Disclosed equity funding

Unlock exact values

About Navitor

Navitor Pharmaceuticals is a pioneering biotech company focused on developing innovative therapeutics that selectively target mTORC1 activity. The company operates in the pharmaceutical and biotechnology market, primarily serving patients with age-related diseases and treatment-resistant depression. Navitor's core product, NV-5138, is an orally active mTORC1 activator designed to address treatment-resistant depression by modulating metabolic pathways in the brain. The business model revolves around research and development, clinical trials, and strategic partnerships, such as their collaboration with Supernus Pharmaceuticals. Navitor generates revenue through licensing agreements, milestone payments, and potential future sales of their therapeutic products.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2010
Headquarters: Cambridge, United States
Employees: 7
Open positions: None listed
Dealroom signal: 31.0/100
Industry: Health
Sub-industry: Pharmaceutical, BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Health Diagnostics, Spinout, Biotech and Pharma, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn X

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

6 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
LATE VCOther financing	May 2020	$20M	$81M	Undisclosed	↗
SERIES COther financing	Mar 2018	$11M	$45M	Undisclosed	↗

Showing the latest 2 of 6 recorded eventsBook a demo for the full funding history →

Growth signals

Navitor website traffic

Latest recorded traffic for Navitor is 1K monthly website visits, up 20.5% over the last three months. Navitor's team declined 22.2% over the past year.

Latest monthly visits1K 3-month web change+20.5% 1-year team growth-22.2%

Monthly website visitsOct 2014–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
STSolve TherapeuticsTargeted cancer therapies enhancing safety and precision	San Diego, United States	Operational	35	$296M	$480M
NRNucleus RadioPharmaTransforming lives with radiopharmaceuticals by leveraging world class clinical, development, manufacturing, and supply chain expertise	Davidson, United States	Operational
YTYsotope TheranosticsTargeted radiopharmaceuticals for precision oncology	Madrid, Spain	Operational
RORadionetics OncologyRadionetics Oncology is a precision oncology company focusing on the discovery and development of radiopharmaceuticals	San Diego, United States	Operational
ASAtley SolutionsAutomated, standardised and reproducible production of At-211 radiopharmaceuticals for targeted alpha therapy	Göteborgs Stad, Sweden	Operational
NBNexEos BioNon-invasive imaging agent for diagnosing and managing Eosinophilic Esophagitis, enhancing patient care and disease monitoring	Pottstown, United States	Operational
PRPrecirixCamelid-derived radiopharmaceuticals for targeted cancer therapy	Jette, Belgium	Operational
OXOXcanAI-powered liquid biopsy tests for early cancer detection	Oxford, United Kingdom	Operational